PET3D Conference cancelled due to COVID-19 crisis

May 28, 2020, Loughborough University, UK

https//www.burleigh-court.co.uk/

Keynote speaker Marc Robillard, Tagworks Pharmaceutical

Radiopharmaceuticals in Drug Design and Development:

“Theranostics: combining Imaging and Therapy”

Ciara Finucane, Vice President, Discovery & Preclinical Services, Invicro

“De-risking PET Radioligand Development with the 3 P’s: Pharmacology, Pharmacology, Pharmacology”

Lisa Wells, Head of Discovery CNS Applications, Invicro

“PET in Early Phase Oncology Trials”

Jan Passchier, Global Head of Laboratories and Clinics, Invicro

Programme

Registration 24 hour delegates

Registration 8 hour delegates - Free

About PET3D

This conference is the Final Dissemination Event of the PET3D project, a 4 year EU Marie Sklodowska-Curie Actions training programme for Early Stage Researchers. The aim of the programme is to train the next generation of translational Positron Emission Tomography (PET) imaging scientists who will play a key role in shaping the future of drug design and development.

Research Projects

Find out about the cutting edge research projects in the three main therapeutic areas of oncology, cardiovascular and central nervous system

Find out how we are using PET in Drug Design and Development.

Meet the collaborating PIs from: Loughborough ,UK (Coordinating University); CIC biomaGUNE, Spain; AstraZeneca plc, Sweden; Invicro, UK; Stichting VUMC, The Netherlands; University of Bergen, Norway; Vrije Universiteit Brussel, Belgium; Westfaelische Wilhelms-Universitaet, Muenster, Germany

Keynote External Speaker

Dr Marc Robillard

Tagworks Pharmaceuticals

Radiopharmaceuticals in Drug Design and Developments

Speakers from Invicro, UK will give key talks as part of a PET3D Summer School training event within the PET3D conference.

Ciara Finucane, Vice President, Discovery & Preclinical Services

Lisa Wells, Head of Discovery CNS Applications

Jan Passchier, Global Head of Laboratories and Clinics

How PET can be used in Drug Design and Development

PET is a non-invasive and highly sensitive imaging technology developed to visualise and quantify biochemical and physiological processes in vivo.

Although the PET3D consortium will not develop drugs, it will make a significant contribution to drug development by validating PET imaging in different therapeutic areas.

Within the consortium we have leading experts – from 8 different institutions situated all over Europe – in medicinal and organic chemistry, peptide and protein chemistry, radiochemistry, pharmacology, cell and preclinical biology, molecular biology, molecular imaging, image analysis and radiology.

All beneficiaries of the project have a PET centre onsite with the exception of AstraZeneca, which is the ‘big pharma’ partner whose role is to provide a proof-of principle validation and essential input on the research activity developed within PET3D.